Clinical trials show changing role of existing treatment and introduction of newer medications
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Drug UPDATES
Information on New Approvals and Medication Safety
Ethics FORUM
Understanding the challenges in rheumatology today
Treat JIA Without Slowing Growth
Etanercept does not impede normal height and weight development in these patients
Shingles, Chickenpox Hospitalizations Higher for Patients on Anti-TNF Drugs
More research needed to clarify risks and benefits of VZV vaccination
Macrophage Activation Syndrome
A review of diagnosis, treatment, and prognosis
Can Technology Help Solve Scleroderma Renal Crisis?
A case study in using the Internet to facilitate rare disease research
ACR Honors Accomplishments in Rheumatology
Rheumatologists and health professionals recognized for their contributions to the field
New GIOP Guidelines Available
The ACR published new recommendations for the management of glucocorticoid-induced osteoporosis (GIOP) in the November issue of Arthritis Care & Research. These guidelines have been endorsed by the American Society for Bone and Mineral Research. They apply to adult patients receiving oral glucocorticoid therapy.
Naturally Occurring Antibodies May Lead to New RA Therapies
A study published in the Journal of Immunology indicates that naturally occurring antibodies in the human immune system have the capacity to suppress inflammatory responses throughout the body. These antibodies may provide researchers an opportunity to develop new therapies for rheumatoid arthritis (RA) and other inflammatory conditions using similar pathways.
- « Previous Page
- 1
- …
- 273
- 274
- 275
- 276
- 277
- …
- 308
- Next Page »